All In Biotech

Drug Trial Radar · NCT00000556

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

Last checked: Nov 19, 2026Latest source record: Mar 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

Not stated

Start

Mar 1995

Primary completion

Not stated

Study completion Sep 2002

Sponsor

Sponsor type
NIH
First posted
Oct 28, 1999

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, from 65 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.

Conditions

  • Arrhythmia
  • Atrial Fibrillation
  • Cardiovascular Diseases
  • Heart Diseases

Interventions

  • amiodaroneDrug

  • sotalolDrug

  • propafenoneDrug

  • flecainideDrug

  • quinidineDrug

  • moricizineDrug

  • disopyramideDrug

  • procainamideDrug

  • adrenergic beta antagonistsDrug

  • verapamilDrug

  • diltiazemDrug

  • digoxinDrug

  • catheter ablationProcedure

  • pacemaker, artificialDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.